Press Release Apr 17 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Morepen Laboratories Limited has announced the successful completion of a USFDA inspection at its Masulakhanna facility with no adverse observations, marking the fourth consecutive successful inspection for the company. This achievement highlights Morepen's commitment to quality and regulatory standards, enhancing its credibility with global regulators and customers. The company is also expanding into the CDMO space, leveraging its strong regulatory track record and infrastructure.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Morepen Laboratories Limited on 6ix
Earlier from Morepen Laboratories
- Press Release Feb 23 2026
- Press Release (Revised) May 13 2025
- Press Release May 13 2025
- Press Release May 01 2025
- Press Release Apr 29 2025
Later from Morepen Laboratories
- Press Release May 27 2026
- Morepen Laboratories Limited Press Release Jul 01 2026
- Q1'FY27 Investor Presentations
- Morepen Laboratories Limited Press Release Sep 28 2026
- Morepen Laboratories Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Morepen hits record Q2 revenue of Rs. 755 Cr; EBITDA surges 273% to Rs. 132 Cr; CDMO momentum drives Morepen into a new earnings scale; H1 EBITDA reaches Rs. 220 Cr".
Follow Morepen Laboratories into a list and get an email when it puts out news.
Follow Morepen Laboratories